Compare CRMT & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRMT | ACOG |
|---|---|---|
| Founded | 1981 | 2000 |
| Country | United States | Canada |
| Employees | N/A | 57 |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.5M | 110.4M |
| IPO Year | 2026 | N/A |
| Metric | CRMT | ACOG |
|---|---|---|
| Price | $12.95 | $6.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $29.50 | $16.00 |
| AVG Volume (30 Days) | ★ 109.2K | 41.7K |
| Earning Date | 06-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,390,932,000.00 | N/A |
| Revenue This Year | N/A | $139.22 |
| Revenue Next Year | $4.92 | $134.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.58 | $4.50 |
| 52 Week High | $62.55 | $10.88 |
| Indicator | CRMT | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 50.30 |
| Support Level | $11.10 | $5.00 |
| Resistance Level | $13.63 | $6.59 |
| Average True Range (ATR) | 0.96 | 0.42 |
| MACD | 0.21 | -0.06 |
| Stochastic Oscillator | 39.80 | 40.21 |
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.